Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
follicular lymphoma
Biotech
ASH: Regeneron’s near-approval bispecific shines again
Regeneron presented updated data on the lymphoma candidate ahead of an FDA approval decision that is scheduled for March 31.
Nick Paul Taylor
Dec 11, 2023 5:25am
ASH: Regeneron lymphoma med scores but safety muffles excitement
Dec 12, 2022 5:30pm
ESMO: A peak at Pfizer's EZH2 inhibitor flashes hope for some
Sep 11, 2022 6:00am
Nordic Nanovector pulls the plug on troubled Paradigme trial
Jul 6, 2022 11:26am
Nordic Nanovector reviews trial as enrollment grinds to a halt
Jun 2, 2022 8:36am
MEI rocked by FDA request for randomized data on cancer drug
Mar 25, 2022 6:00am
